Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants

Daniele Pastori; Gregory Y. H. Lip; Alessio Farcomeni; Francesco Del Sole; Angela Sciacqua; Francesco Perticone; Rossella Marcucci; Elisa Grifoni; Pasquale Pignatelli; Francesco Violi

doi:10.1016/j.dib.2018.01.109

Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants

Daniele Pastori, Gregory Y. H. Lip, Alessio Farcomeni, Francesco Del Sole, Angela Sciacqua, Francesco Perticone, Rossella Marcucci, Elisa Grifoni, Pasquale Pignatelli, Francesco Violi

Cardiovascular Sciences

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

128 Downloads (Pure)

Abstract

This article contains the data showing the different characteristics of atrial fibrillation (AF) patients treated with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) screened for the presence of liver fibrosis (LF) and followed to record the occurrence of bleeding and cardiovascular events (CVEs). A detailed description of major and minor bleedings is provided according to anticoagulant treatment (VKAs vs. NOACs) and to the presence of LF.

Data here reported also show a higher incidence rate of CVEs in VKA-treated patients, but not in those on NOACs. The data are supplemental to our original research article titled “Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonists oral anticoagulants” (Pastori et al., 2018) [1].

Original language	English
Pages (from-to)	830-836
Journal	Data in Brief
Volume	17
Early online date	6 Feb 2018
DOIs	https://doi.org/10.1016/j.dib.2018.01.109
Publication status	Published - 1 Apr 2018

Access to Document

10.1016/j.dib.2018.01.109Licence: Creative Commons: Attribution (CC BY)

Pastori_et_al_Data_on_incidence_Data_in_Brief_2018
Published in Data in Brief on 06/02/2018 DOI: 10.1016/j.dib.2018.01.109
Final published version, 348 KBLicence: Creative Commons: Attribution (CC BY)

https://www.sciencedirect.com/science/article/pii/S2352340918301136Licence: Creative Commons: Attribution (CC BY)

Cite this

Pastori, D., Lip, G. Y. H., Farcomeni, A., Del Sole, F., Sciacqua, A., Perticone, F., Marcucci, R., Grifoni, E., Pignatelli, P., & Violi, F. (2018). Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. Data in Brief, 17, 830-836. Advance online publication. https://doi.org/10.1016/j.dib.2018.01.109

@article{09cb4afb36ac455fab2a3ba7c607f494,

title = "Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants",

abstract = "This article contains the data showing the different characteristics of atrial fibrillation (AF) patients treated with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) screened for the presence of liver fibrosis (LF) and followed to record the occurrence of bleeding and cardiovascular events (CVEs). A detailed description of major and minor bleedings is provided according to anticoagulant treatment (VKAs vs. NOACs) and to the presence of LF.Data here reported also show a higher incidence rate of CVEs in VKA-treated patients, but not in those on NOACs. The data are supplemental to our original research article titled “Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonists oral anticoagulants” (Pastori et al., 2018) [1].",

author = "Daniele Pastori and Lip, {Gregory Y. H.} and Alessio Farcomeni and {Del Sole}, Francesco and Angela Sciacqua and Francesco Perticone and Rossella Marcucci and Elisa Grifoni and Pasquale Pignatelli and Francesco Violi",

year = "2018",

month = apr,

day = "1",

doi = "10.1016/j.dib.2018.01.109",

language = "English",

volume = "17",

pages = "830--836",

journal = "Data in Brief",

issn = "2352-3409",

publisher = "Elsevier",

}

Pastori, D, Lip, GYH, Farcomeni, A, Del Sole, F, Sciacqua, A, Perticone, F, Marcucci, R, Grifoni, E, Pignatelli, P & Violi, F 2018, 'Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants', Data in Brief, vol. 17, pp. 830-836. https://doi.org/10.1016/j.dib.2018.01.109

TY - JOUR

T1 - Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants

AU - Pastori, Daniele

AU - Lip, Gregory Y. H.

AU - Farcomeni, Alessio

AU - Del Sole, Francesco

AU - Sciacqua, Angela

AU - Perticone, Francesco

AU - Marcucci, Rossella

AU - Grifoni, Elisa

AU - Pignatelli, Pasquale

AU - Violi, Francesco

PY - 2018/4/1

Y1 - 2018/4/1

N2 - This article contains the data showing the different characteristics of atrial fibrillation (AF) patients treated with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) screened for the presence of liver fibrosis (LF) and followed to record the occurrence of bleeding and cardiovascular events (CVEs). A detailed description of major and minor bleedings is provided according to anticoagulant treatment (VKAs vs. NOACs) and to the presence of LF.Data here reported also show a higher incidence rate of CVEs in VKA-treated patients, but not in those on NOACs. The data are supplemental to our original research article titled “Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonists oral anticoagulants” (Pastori et al., 2018) [1].

AB - This article contains the data showing the different characteristics of atrial fibrillation (AF) patients treated with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) screened for the presence of liver fibrosis (LF) and followed to record the occurrence of bleeding and cardiovascular events (CVEs). A detailed description of major and minor bleedings is provided according to anticoagulant treatment (VKAs vs. NOACs) and to the presence of LF.Data here reported also show a higher incidence rate of CVEs in VKA-treated patients, but not in those on NOACs. The data are supplemental to our original research article titled “Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonists oral anticoagulants” (Pastori et al., 2018) [1].

U2 - 10.1016/j.dib.2018.01.109

DO - 10.1016/j.dib.2018.01.109

M3 - Article

SN - 2352-3409

VL - 17

SP - 830

EP - 836

JO - Data in Brief

JF - Data in Brief

ER -

Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants

Abstract

Access to Document

Fingerprint

Cite this